Coma After Droperidol Administration: A Case Report.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
In Switzerland, approximately 32,000 patients are hospitalized annually due to adverse drug reactions (ADRs), representing 2.3% of all hospitalizations. During the perioperative period, the administration of a variety of drugs from different classes over a relatively short period of time increases the risk of ADR. Here, we describe the case of a 32-year-old woman who was administered droperidol to treat nausea in the recovery room after a myomectomy and who subsequently became comatose. Correctable metabolic, respiratory, and cerebrovascular disorders were ruled out. Six hours after the event, she was extubated without residual effects. We discuss potential ADR for droperidol.
Identifiants
pubmed: 39137114
doi: 10.1213/XAA.0000000000001831
pii: 02054229-202408000-00005
doi:
Substances chimiques
Droperidol
O9U0F09D5X
Antiemetics
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01831Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Milde AS, Motsch J. Medikamenteninteraktionen für den Anästheisten [Drug interactions and the anesthesiologist]. Anaesthesist. 2003;52:839–859.
Eilers H, Niemann C. Clinically important drug interactions with intravenous anaesthetics in older patients. Drugs Aging. 2003;20:969–980.
Beeler PE, Stammschulte T, Dressel H. Hospitalisations related to adverse drug reactions in Switzerland in 2012–2019: characteristics, in-hospital mortality, and spontaneous reporting rate. Drug Saf. 2023;46:753–763.
Jin Z, Gan TJ, Bergese SD. Prevention and treatment of postoperative nausea and vomiting (PONV): a review of current recommendations and emerging therapies. Ther Clin Risk Manag. 2020;16:1305–1317.
Kim HK, Leonard JB, Corwell BN, Connors NJ. Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium. Expert Opin Drug Saf. 2021;20:123–138.
Wille RT, Barnett JL, Chey WD, Scheiman JM, Elta GH. Routine droperidol pre-medication improves sedation for ERCP. Gastrointest Endosc. 2000;52:362–366.
McKeage K, Simpson D, Wagstaff AJ. Intravenous Droperidol. Drugs. 2006;66:2123–2147.
Cressman WA, Plostnieks J, Johnson PC. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. Anesthesiology. 1973;38:363–369.
Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8:94.
Koo JY, Chien CP. Coma following ECT and intravenous droperidol: case report. J Clin Psychiatry. 1986;47:94–95.
Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094–1100.
Lai PC, Huang YT. Evidence-based review and appraisal of the use of droperidol in the emergency department. Ci Ji Yi Xue Za Zhi. 2018;30:1–4.
Edge R, Argáez C. CADTH health technology review. Droperidol for agitation in acute care. Canadian Agency for Drugs and Technologies in Health Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.; 2021.
Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64:1174–1186.
Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000;47:537–551.